State Street Corp Has $43.09 Million Stake in Certara, Inc. (NASDAQ:CERT)

State Street Corp boosted its holdings in shares of Certara, Inc. (NASDAQ:CERT - Free Report) by 3.4% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 3,679,699 shares of the company's stock after acquiring an additional 122,411 shares during the quarter. State Street Corp owned 2.29% of Certara worth $43,089,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of the business. Petrus Trust Company LTA acquired a new stake in shares of Certara during the third quarter worth approximately $994,000. Paloma Partners Management Co purchased a new stake in Certara in the 3rd quarter worth approximately $413,000. 272 Capital LP acquired a new stake in shares of Certara during the 3rd quarter valued at $177,000. Wasatch Advisors LP grew its holdings in shares of Certara by 22.4% during the 3rd quarter. Wasatch Advisors LP now owns 9,015,941 shares of the company's stock valued at $105,577,000 after acquiring an additional 1,651,076 shares in the last quarter. Finally, Edgestream Partners L.P. purchased a new position in shares of Certara during the 3rd quarter valued at $1,782,000. Hedge funds and other institutional investors own 73.96% of the company's stock.

Insider Activity at Certara

In other news, insider Patrick F. Smith sold 5,409 shares of the business's stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $11.03, for a total transaction of $59,661.27. Following the transaction, the insider now owns 50,091 shares in the company, valued at approximately $552,503.73. The trade was a 9.75 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 2.39% of the stock is owned by corporate insiders.

Certara Stock Performance

Shares of Certara stock traded up $0.16 on Friday, reaching $10.71. The stock had a trading volume of 3,240,121 shares, compared to its average volume of 852,739. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.86 and a current ratio of 2.86. The business's 50-day moving average price is $10.83 and its two-hundred day moving average price is $12.51. The stock has a market cap of $1.72 billion, a P/E ratio of -53.55, a price-to-earnings-growth ratio of 5.86 and a beta of 1.53. Certara, Inc. has a fifty-two week low of $9.41 and a fifty-two week high of $19.87.

Certara (NASDAQ:CERT - Get Free Report) last released its earnings results on Wednesday, November 6th. The company reported $0.13 earnings per share for the quarter, topping analysts' consensus estimates of $0.11 by $0.02. The firm had revenue of $94.80 million during the quarter, compared to analyst estimates of $95.51 million. Certara had a negative net margin of 8.34% and a positive return on equity of 3.43%. The business's revenue was up 10.7% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.06 EPS. On average, sell-side analysts forecast that Certara, Inc. will post 0.28 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on CERT. Robert W. Baird reduced their price objective on Certara from $18.00 to $13.00 and set a "neutral" rating for the company in a research report on Tuesday, November 5th. Barclays decreased their target price on shares of Certara from $14.00 to $12.00 and set an "equal weight" rating for the company in a research report on Thursday, November 7th. Finally, UBS Group upgraded shares of Certara from a "neutral" rating to a "buy" rating and set a $16.00 price target on the stock in a report on Friday, September 27th. Six investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company's stock. According to data from MarketBeat, Certara has a consensus rating of "Hold" and a consensus price target of $15.92.

Certara Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.